What concerns do patients bring up and how might they be addressed?

Many patients find the infusion process onerous as well, since they must be in a location where there is immediate access to medications to treat a severe infusion reaction (eg, anaphylaxis) and must be under observation for an hour following the infusion to monitor for adverse effects.

Nevertheless, these agents have shown a high level of efficacy in treating COVID-19 and these practical concerns should not deter clinicians from referring patients for treatment.

I encourage clinicians to provide patients with reliable resources for education about antibody therapy (Table 1). There are many misconceptions in this day and age about all aspects of COVID-19 that accurate information is essential and will also encourage eligible patients to be treated with antibody therapy.

Continue Reading

Table 1

Patient Education Websites

National Infusion Center Association

US Department of Health and Human Services


  1. Yang X, Liu Y, Liu Y, Yang Q, Wu X, Huang X, Liu H, Cai W, Ma G. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. Expert Rev Clin Pharmacol. Published online August 4, 2020. doi.org/10.1080/17512433.2020.1805315.
  2. US Department of Health and Human Services. Monoclonal antibodies for high-risk COVID-19 patients. Available at: https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients?gclid=Cj0KCQjwp86EBhD7ARIsAFkgakgUA8WIBY5QrBB4OmlGl1dPvhwPRsUIgp3g9T9P8OVw7c_x2Kv4kT8aAvv0EALw_wcB. Accessed: April 13, 2021.
  3. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Chi-Chung Cheng V, et al. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. April 14, 2021. Available at: https://www.idsociety.org/COVID19guidelines Accessed: April 20, 2021.
  4. Infectious Disease Society of America. Monoclonal Antibodies. Available at: https://www.idsociety.org/covid-19-real-time-learning-network/therapeutics-and-interventions/monoclonal-antibodies/. Accessed: April 30, 2021.
  5. National Institutes of Health (NIH). Anti-SARS-CoV-2 Monoclonal Antibodies. Available at: https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/. Accessed: April 21, 2021.
  6. Centers for Disease Control and Prevention (CDC). Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Paged reviewed May 14, 2021. Available at: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html Accessed: May 16, 2021.
  7. US Department of Health and Human Services. Biden Administration to Invest $150 Million to Expand Access to COVID-19 Treatments in Underserved Communities March 17, 2021. Available at: https://www.hhs.gov/about/news/2021/03/17/biden-administration-to-invest-150-million-to-expand-access-to-covid-19-treatments-in-underserved-communities.html. Accessed: April 18, 2021.